1. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States 
Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Mai Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer, Ajai Chari 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 2, Pages (February 2018)
DOI: /j.clml
Copyright © 2018 The Authors Terms and Conditions

2. Figure 1
Study Period
Abbreviations: 1LT = first-line Therapy; 2LT = second-line Therapy; MM = multiple myeloma.
Clinical Lymphoma, Myeloma and Leukemia  , DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

3. Figure 2
Relationship Between Second-Line Therapy Duration and Time to Next Therapy. aTTNT Kaplan-Meier Curve Represents Proportion of Progression-free Patients; DOT Kaplan-Meier Curve Represents Proportion of Patients Still Receiving Therapy
Abbreviations: CI = confidence interval; DOT = duration of therapy; 2LT = second-line therapy; TTNT = time to next therapy.
Clinical Lymphoma, Myeloma and Leukemia  , DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

4. Figure 3
Predicteda Probability of 1-Year Overall Survival by Duration of Second-Line Therapy (2LT), Overall (Panel A), Stratified by Age (Panel B), and the Presence vs Absence of Comorbidities (Panel C). aControlling for Age; Gender; Race; Cytogenetic Risk; Comorbidities of Interest; Charlson Comorbidity Index; CRAB (Hypercalcemia, Renal Insufficiency, Anemia, Bone Lesions) Symptoms; Geographic Region; Insurance Type; TFI Before 2LT; 1LT/2LT Regimen Type; Year of Diagnosis; Time Since Initial Diagnosis; Time-Dependent, Treatment-, and Multiple Myeloma (MM)-Related Confounders; and Post-2LT Regimens. Odds ratio (OR) Represents the Odds of 1-Year Mortality for Each Additional Month of Continued Therapy
Abbreviations: CI = confidence interval; DOT = duration of therapy; 1LT = first-line therapy; RRMM = relapsed/refractory MM.
Clinical Lymphoma, Myeloma and Leukemia  , DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

5. Figure 4
Percentage of Increase in 1-Year Overall Survival (OS) Relative to Median Duration of Second-Line Therapy (6.9 Months)
Abbreviations: DOT = duration of therapy; 2LT = second-line therapy.
Clinical Lymphoma, Myeloma and Leukemia  , DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions